Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rifamycin sv + placebo
- Development stage
- Unknown
- Lead developer
- COSMO GROUP
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Rifamycin SV + placebo refers to a clinical trial design where rifamycin SV is compared to placebo. Rifamycin SV is an antibacterial drug that inhibits bacterial DNA-dependent RNA synthesis by binding to prokaryotic RNA polymerase. It is primarily used for the treatment of travelers' diarrhea caused by noninvasive strains of E. coli. The drug is formulated as a delayed-release tablet with a pH-resistant polymer film that breaks down above pH 7, allowing targeted delivery to the intestine.
- Brand names
- Aemcolo
- Other names
- rifamycin SV MMX
02
Targets
RNAP (Bacterial dna-dependent RNA polymerase)
Beyond the preview
Go deeper on rifamycin sv + placebo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rifamycin sv + placebo.